Listed

Mineralys Therapeutics, Inc.

MLYSNasdaqCIK 1933414HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$246.0m, Q2 FY2026
Net income−$241.1m, Q2 FY2026
Mineralys Therapeutics, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Research and development$m22.5Research and development, Q3 FY2023, three months to 2023-09-30$22.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-12, accession 0001933414-24-000057.Report this figure23.7Research and development, Q4 FY2023, three months to 2023-12-31$23.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-02-12, accession 0001933414-25-000009. Derived: 12-month figure less the 9-month figure.Report this figure30.8Research and development, Q1 FY2024, three months to 2024-03-31$30.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-12, accession 0001933414-25-000058.Report this figure39.3Research and development, Q2 FY2024, three months to 2024-06-30$39.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-12, accession 0001933414-25-000090.Report this figure54.0Research and development, Q3 FY2024, three months to 2024-09-30$54.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-10, accession 0001933414-25-000142.Report this figure44.6Research and development, Q4 FY2024, three months to 2024-12-31$44.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-12, accession 0001933414-26-000056. Derived: 12-month figure less the 9-month figure.Report this figure37.9Research and development, Q1 FY2025, three months to 2025-03-31$37.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-06, accession 0001933414-26-000084.Report this figure38.3Research and development, Q2 FY2025, three months to 2025-06-30$38.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-11, accession 0001933414-26-000114.Report this figure31.5Research and development, Q3 FY2025, three months to 2025-09-30$31.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-10, accession 0001933414-25-000142.Report this figure24.4Research and development, Q4 FY2025, three months to 2025-12-31$24.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-12, accession 0001933414-26-000056. Derived: 12-month figure less the 9-month figure.Report this figure24.4Research and development, Q1 FY2026, three months to 2026-03-31$24.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-06, accession 0001933414-26-000084.Report this figure221Research and development, Q2 FY2026, three months to 2026-06-30$221.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-11, accession 0001933414-26-000114.Report this figure
Operating income$m(26.3)Operating income, Q3 FY2023, three months to 2023-09-30−$26.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-12, accession 0001933414-24-000057.Report this figure(27.7)Operating income, Q4 FY2023, three months to 2023-12-31−$27.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-12, accession 0001933414-25-000009. Derived: 12-month figure less the 9-month figure.Report this figure(35.4)Operating income, Q1 FY2024, three months to 2024-03-31−$35.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-12, accession 0001933414-25-000058.Report this figure(45.2)Operating income, Q2 FY2024, three months to 2024-06-30−$45.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-12, accession 0001933414-25-000090.Report this figure(60.1)Operating income, Q3 FY2024, three months to 2024-09-30−$60.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-10, accession 0001933414-25-000142.Report this figure(51.8)Operating income, Q4 FY2024, three months to 2024-12-31−$51.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-12, accession 0001933414-26-000056. Derived: 12-month figure less the 9-month figure.Report this figure(44.4)Operating income, Q1 FY2025, three months to 2025-03-31−$44.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-06, accession 0001933414-26-000084.Report this figure(46.7)Operating income, Q2 FY2025, three months to 2025-06-30−$46.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-11, accession 0001933414-26-000114.Report this figure(41.1)Operating income, Q3 FY2025, three months to 2025-09-30−$41.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-10, accession 0001933414-25-000142.Report this figure(38.3)Operating income, Q4 FY2025, three months to 2025-12-31−$38.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-12, accession 0001933414-26-000056. Derived: 12-month figure less the 9-month figure.Report this figure(45.3)Operating income, Q1 FY2026, three months to 2026-03-31−$45.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-06, accession 0001933414-26-000084.Report this figure(246)Operating income, Q2 FY2026, three months to 2026-06-30−$246.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-11, accession 0001933414-26-000114.Report this figure
Income tax$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported0.0Income tax, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-12, accession 0001933414-26-000056. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported
Net income$m(22.8)Net income, Q3 FY2023, three months to 2023-09-30−$22.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-12, accession 0001933414-24-000057.Report this figure(24.4)Net income, Q4 FY2023, three months to 2023-12-31−$24.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-12, accession 0001933414-25-000009. Derived: 12-month figure less the 9-month figure.Report this figure(31.5)Net income, Q1 FY2024, three months to 2024-03-31−$31.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-10, accession 0001933414-25-000142.Report this figure(41.0)Net income, Q2 FY2024, three months to 2024-06-30−$41.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-10, accession 0001933414-25-000142.Report this figure(56.3)Net income, Q3 FY2024, three months to 2024-09-30−$56.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-10, accession 0001933414-25-000142.Report this figure(48.9)Net income, Q4 FY2024, three months to 2024-12-31−$48.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-12, accession 0001933414-26-000056. Derived: 12-month figure less the 9-month figure.Report this figure(42.2)Net income, Q1 FY2025, three months to 2025-03-31−$42.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001933414-26-000114.Report this figure(43.3)Net income, Q2 FY2025, three months to 2025-06-30−$43.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001933414-26-000114.Report this figure(36.9)Net income, Q3 FY2025, three months to 2025-09-30−$36.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-10, accession 0001933414-25-000142.Report this figure(32.2)Net income, Q4 FY2025, three months to 2025-12-31−$32.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-12, accession 0001933414-26-000056. Derived: 12-month figure less the 9-month figure.Report this figure(39.3)Net income, Q1 FY2026, three months to 2026-03-31−$39.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001933414-26-000114.Report this figure(241)Net income, Q2 FY2026, three months to 2026-06-30−$241.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001933414-26-000114.Report this figure
Diluted EPS$ per share(0.57)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.57 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-12, accession 0001933414-24-000057.Report this figurenot reported(0.70)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.70 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-12, accession 0001933414-25-000058.Report this figure(0.83)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.83 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-12, accession 0001933414-25-000090.Report this figure(1.13)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$1.13 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-10, accession 0001933414-25-000142.Report this figurenot reported(0.79)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.79 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-06, accession 0001933414-26-000084.Report this figure(0.66)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.66 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001933414-26-000114.Report this figure(0.52)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.52 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-10, accession 0001933414-25-000142.Report this figurenot reported(0.47)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.47 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-06, accession 0001933414-26-000084.Report this figure(2.85)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$2.85 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001933414-26-000114.Report this figure
Basic EPS$ per share(0.57)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.57 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-12, accession 0001933414-24-000057.Report this figurenot reported(0.70)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.70 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-12, accession 0001933414-25-000058.Report this figure(0.83)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.83 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-12, accession 0001933414-25-000090.Report this figure(1.13)Basic EPS, Q3 FY2024, three months to 2024-09-30−$1.13 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-10, accession 0001933414-25-000142.Report this figurenot reported(0.79)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.79 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-06, accession 0001933414-26-000084.Report this figure(0.66)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.66 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-11, accession 0001933414-26-000114.Report this figure(0.52)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.52 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-10, accession 0001933414-25-000142.Report this figurenot reported(0.47)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.47 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-06, accession 0001933414-26-000084.Report this figure(2.85)Basic EPS, Q2 FY2026, three months to 2026-06-30−$2.85 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-11, accession 0001933414-26-000114.Report this figure

Balance sheet

Cash and equivalents$138.3m, Q2 FY2026
Long-term debt$100.0k, Q2 FY2026
Shareholders' equity$550.9m, Q2 FY2026
Mineralys Therapeutics, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m86.3Cash and equivalents, Q3 FY2023, at 2023-09-30$86.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-07, accession 0001933414-23-000087.Report this figure49.3Cash and equivalents, FY2023, at 2023-12-31$49.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-02-12, accession 0001933414-25-000009.Report this figure90.4Cash and equivalents, Q1 FY2024, at 2024-03-31$90.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-09, accession 0001933414-24-000016.Report this figure67.9Cash and equivalents, Q2 FY2024, at 2024-06-30$67.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-13, accession 0001933414-24-000039.Report this figure97.3Cash and equivalents, Q3 FY2024, at 2024-09-30$97.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-12, accession 0001933414-24-000057.Report this figure114Cash and equivalents, FY2024, at 2024-12-31$114.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-12, accession 0001933414-26-000056.Report this figure165Cash and equivalents, Q1 FY2025, at 2025-03-31$165.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-12, accession 0001933414-25-000058.Report this figure102Cash and equivalents, Q2 FY2025, at 2025-06-30$101.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-12, accession 0001933414-25-000090.Report this figure218Cash and equivalents, Q3 FY2025, at 2025-09-30$217.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-10, accession 0001933414-25-000142.Report this figure173Cash and equivalents, FY2025, at 2025-12-31$172.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-11, accession 0001933414-26-000114.Report this figure113Cash and equivalents, Q1 FY2026, at 2026-03-31$112.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-06, accession 0001933414-26-000084.Report this figure138Cash and equivalents, Q2 FY2026, at 2026-06-30$138.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-11, accession 0001933414-26-000114.Report this figure
Current assets$m265Current assets, Q3 FY2023, at 2023-09-30$265.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-07, accession 0001933414-23-000087.Report this figure249Current assets, FY2023, at 2023-12-31$249.1m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-02-12, accession 0001933414-25-000009.Report this figure347Current assets, Q1 FY2024, at 2024-03-31$346.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-09, accession 0001933414-24-000016.Report this figure318Current assets, Q2 FY2024, at 2024-06-30$318.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-13, accession 0001933414-24-000039.Report this figure268Current assets, Q3 FY2024, at 2024-09-30$267.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-12, accession 0001933414-24-000057.Report this figure205Current assets, FY2024, at 2024-12-31$205.4m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-12, accession 0001933414-26-000056.Report this figure355Current assets, Q1 FY2025, at 2025-03-31$354.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-12, accession 0001933414-25-000058.Report this figure335Current assets, Q2 FY2025, at 2025-06-30$335.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-12, accession 0001933414-25-000090.Report this figure600Current assets, Q3 FY2025, at 2025-09-30$599.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-10, accession 0001933414-25-000142.Report this figure661Current assets, FY2025, at 2025-12-31$661.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-11, accession 0001933414-26-000114.Report this figure652Current assets, Q1 FY2026, at 2026-03-31$652.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-06, accession 0001933414-26-000084.Report this figure666Current assets, Q2 FY2026, at 2026-06-30$665.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-11, accession 0001933414-26-000114.Report this figure
Total assets$m278Total assets, Q3 FY2023, at 2023-09-30$277.6m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-07, accession 0001933414-23-000087.Report this figure252Total assets, FY2023, at 2023-12-31$251.6m. XBRL concept us-gaap:Assets. 10-K filed 2025-02-12, accession 0001933414-25-000009.Report this figure347Total assets, Q1 FY2024, at 2024-03-31$347.2m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-09, accession 0001933414-24-000016.Report this figure318Total assets, Q2 FY2024, at 2024-06-30$318.5m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-13, accession 0001933414-24-000039.Report this figure268Total assets, Q3 FY2024, at 2024-09-30$268.3m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-12, accession 0001933414-24-000057.Report this figure206Total assets, FY2024, at 2024-12-31$205.9m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-12, accession 0001933414-26-000056.Report this figure355Total assets, Q1 FY2025, at 2025-03-31$354.9m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-12, accession 0001933414-25-000058.Report this figure336Total assets, Q2 FY2025, at 2025-06-30$335.7m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-12, accession 0001933414-25-000090.Report this figure600Total assets, Q3 FY2025, at 2025-09-30$599.9m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-10, accession 0001933414-25-000142.Report this figure662Total assets, FY2025, at 2025-12-31$661.8m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-11, accession 0001933414-26-000114.Report this figure653Total assets, Q1 FY2026, at 2026-03-31$652.9m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-06, accession 0001933414-26-000084.Report this figure668Total assets, Q2 FY2026, at 2026-06-30$667.9m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-11, accession 0001933414-26-000114.Report this figure
Current liabilities$m13.5Current liabilities, Q3 FY2023, at 2023-09-30$13.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-07, accession 0001933414-23-000087.Report this figure10.5Current liabilities, FY2023, at 2023-12-31$10.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-02-12, accession 0001933414-25-000009.Report this figure19.2Current liabilities, Q1 FY2024, at 2024-03-31$19.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-09, accession 0001933414-24-000016.Report this figure28.4Current liabilities, Q2 FY2024, at 2024-06-30$28.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-13, accession 0001933414-24-000039.Report this figure31.3Current liabilities, Q3 FY2024, at 2024-09-30$31.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-12, accession 0001933414-24-000057.Report this figure14.6Current liabilities, FY2024, at 2024-12-31$14.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-12, accession 0001933414-26-000056.Report this figure13.4Current liabilities, Q1 FY2025, at 2025-03-31$13.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-12, accession 0001933414-25-000058.Report this figure22.2Current liabilities, Q2 FY2025, at 2025-06-30$22.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-12, accession 0001933414-25-000090.Report this figure23.5Current liabilities, Q3 FY2025, at 2025-09-30$23.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-10, accession 0001933414-25-000142.Report this figure15.1Current liabilities, FY2025, at 2025-12-31$15.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-11, accession 0001933414-26-000114.Report this figure14.7Current liabilities, Q1 FY2026, at 2026-03-31$14.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-06, accession 0001933414-26-000084.Report this figure19.3Current liabilities, Q2 FY2026, at 2026-06-30$19.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-11, accession 0001933414-26-000114.Report this figure
Total liabilities$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported15.1Total liabilities, FY2025, at 2025-12-31$15.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-11, accession 0001933414-26-000114.Report this figurenot reported117Total liabilities, Q2 FY2026, at 2026-06-30$116.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-11, accession 0001933414-26-000114.Report this figure
Long-term debt$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported0.1Long-term debt, Q2 FY2026, at 2026-06-30$100.0k. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2026-08-11, accession 0001933414-26-000114.Report this figure
Shareholders' equity$m264Shareholders' equity, Q3 FY2023, at 2023-09-30$264.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-12, accession 0001933414-24-000057.Report this figure241Shareholders' equity, FY2023, at 2023-12-31$241.2m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-12, accession 0001933414-26-000056.Report this figure328Shareholders' equity, Q1 FY2024, at 2024-03-31$328.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-10, accession 0001933414-25-000142.Report this figure290Shareholders' equity, Q2 FY2024, at 2024-06-30$290.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-10, accession 0001933414-25-000142.Report this figure237Shareholders' equity, Q3 FY2024, at 2024-09-30$236.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-10, accession 0001933414-25-000142.Report this figure191Shareholders' equity, FY2024, at 2024-12-31$191.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001933414-26-000114.Report this figure342Shareholders' equity, Q1 FY2025, at 2025-03-31$341.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001933414-26-000114.Report this figure314Shareholders' equity, Q2 FY2025, at 2025-06-30$313.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001933414-26-000114.Report this figure576Shareholders' equity, Q3 FY2025, at 2025-09-30$576.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-10, accession 0001933414-25-000142.Report this figure647Shareholders' equity, FY2025, at 2025-12-31$646.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001933414-26-000114.Report this figure638Shareholders' equity, Q1 FY2026, at 2026-03-31$638.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001933414-26-000114.Report this figure551Shareholders' equity, Q2 FY2026, at 2026-06-30$550.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001933414-26-000114.Report this figure

Cash flow

Operating cash flow−$32.6m, Q2 FY2026
Capital expenditure$15.0k, Q4 FY2025
Mineralys Therapeutics, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(19.0)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$19.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-12, accession 0001933414-24-000057. Derived: 9-month figure less the 6-month figure.Report this figure(29.0)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$29.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-12, accession 0001933414-25-000009. Derived: 12-month figure less the 9-month figure.Report this figure(19.1)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$19.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-12, accession 0001933414-25-000058.Report this figure(30.1)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$30.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-12, accession 0001933414-25-000090. Derived: 6-month figure less the 3-month figure.Report this figure(50.2)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$50.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-10, accession 0001933414-25-000142. Derived: 9-month figure less the 6-month figure.Report this figure(66.8)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$66.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-12, accession 0001933414-26-000056. Derived: 12-month figure less the 9-month figure.Report this figure(45.5)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$45.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-06, accession 0001933414-26-000084.Report this figure(30.2)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$30.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-11, accession 0001933414-26-000114. Derived: 6-month figure less the 3-month figure.Report this figure(28.9)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$28.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-10, accession 0001933414-25-000142. Derived: 9-month figure less the 6-month figure.Report this figure(37.9)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$37.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-12, accession 0001933414-26-000056. Derived: 12-month figure less the 9-month figure.Report this figure(39.5)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$39.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-06, accession 0001933414-26-000084.Report this figure(32.6)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$32.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-11, accession 0001933414-26-000114. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.0Capital expenditure, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2024-11-12, accession 0001933414-24-000057. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2023, three months to 2023-12-31$0. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-K filed 2025-02-12, accession 0001933414-25-000009. Derived: 12-month figure less the 9-month figure.Report this figure0.1Capital expenditure, Q1 FY2024, three months to 2024-03-31$59.0k. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2025-05-12, accession 0001933414-25-000058.Report this figure0.0Capital expenditure, Q2 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2025-08-12, accession 0001933414-25-000090. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2024, three months to 2024-09-30$37.0k. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2025-11-10, accession 0001933414-25-000142. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-K filed 2026-03-12, accession 0001933414-26-000056. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2025-05-12, accession 0001933414-25-000058.Report this figure0.0Capital expenditure, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2025-08-12, accession 0001933414-25-000090. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2025-11-10, accession 0001933414-25-000142. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2025, three months to 2025-12-31$15.0k. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-K filed 2026-03-12, accession 0001933414-26-000056. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported

Shares

Diluted shares (weighted)84.73m, Q2 FY2026
Mineralys Therapeutics, Inc., shares, quarterly
Line itemUnitperiod not labelled2022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares5.2Diluted shares (weighted), period not labelled, three months to 2022-09-305,181,410 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-07, accession 0001933414-23-000087.Report this figure24.8Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3124,764,469 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-09, accession 0001933414-24-000016.Report this figure39.8Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3039,754,981 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-13, accession 0001933414-24-000039.Report this figure39.9Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3039,930,748 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-12, accession 0001933414-24-000057.Report this figure44.9Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3144,900,755 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-12, accession 0001933414-25-000058.Report this figure49.4Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3049,356,287 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-12, accession 0001933414-25-000090.Report this figure49.8Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3049,815,186 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-10, accession 0001933414-25-000142.Report this figure53.2Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3153,163,551 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-06, accession 0001933414-26-000084.Report this figure65.5Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3065,451,297 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-11, accession 0001933414-26-000114.Report this figure70.6Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3070,594,504 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-10, accession 0001933414-25-000142.Report this figure82.8Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3182,834,752 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-06, accession 0001933414-26-000084.Report this figure84.7Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3084,727,282 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-11, accession 0001933414-26-000114.Report this figure

Shares outstanding: 88.41mShares outstanding, period not labelled, at 2026-08-0388,406,885 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-11, accession 0001933414-26-000114.Report this figure at Aug 3, 2026, from the cover of the 10-Q filed Aug 11, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. Listed shows no prices and gives no investment advice.